NEW YORK − Biotech company Kinnate is slowly exiting out of stealth mode with a pipeline that features two targeted drug candidates expected to enter clinical trials next year. The company is particularly eager to explore its lead product, a RAF inhibitor, in non-V600 BRAF-mutated non-small cell lung cancer, colorectal cancer, and melanoma.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try Premium Access now.
You may already have institutional access!
Check if I qualify.
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.